Efavirenz/lamivudine/tenofovir

Efavirenz/lamivudine/tenofovir
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleoside reverse transcriptase inhibitor
Names
Trade namesTelura
Other namesEFV/3TC/TDF
Clinical data
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Routes of
use		By mouth
Defined daily dosenot established[1]

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura, is a fixed-dose combination medication for the treatment of HIV/AIDS.[2] It combines efavirenz, lamivudine, and tenofovir disoproxil.[2] As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[3] It is taken by mouth.[2]

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[2] Severe side effects may include depression, psychosis, or osteonecrosis.[2] In those with a history of epilepsy, it may increase the frequency of seizures.[2] Greater care should also be taken in those with kidney problems.[2] It is unclear if use during pregnancy is safe.[2][4]

It is on the World Health Organization's List of Essential Medicines.[5] A year of medication is estimated to costs 154 USD in the developing world as of 2011.[2] The combination received tentative approval in the United States in 2014.[6] Its availability and importance is supported by Medecins Sans Frontieres.[2]

Dosage

The defined daily dose is not established[1]

References

  1. 1 2 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 11 September 2020.
  2. 1 2 3 4 5 6 7 8 9 10 "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO). Archived from the original on 2015-10-26. Retrieved 2020-02-03.
  3. ↑ World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  4. ↑ "Telura" (PDF). Mylan.in. 2014. Archived from the original (PDF) on 14 December 2017. Retrieved 13 December 2017.
  5. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  6. ↑ "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". FDA. Archived from the original on 1 December 2017. Retrieved 13 December 2017.
Identifiers:
  • "Efavirenz". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-07-30. Retrieved 2020-08-03.
  • "Lamivudine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-04-17. Retrieved 2020-08-03.
  • "Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-01-25. Retrieved 2020-08-03.
  • "Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2019-06-28. Retrieved 2020-08-03.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.